KDDF-201402-01

Generic Name: KDDF-201402-01

Clinical Trials

Pre-operative Intra-nasal Dexmedetomidine or Insulin for Prevention of Early Post-operative Cognitive Dysfunction in Patients Undergoing Elective Coronary Artery Bypass Graft.

Early Phase 1

Not yet recruiting

Conditions: Post Operative Cognitive Dysfunction

Interventions: Drug: Intranasal dexmedetomidine
Drug: intranasal saline group
Drug: intranasal insulin

First Posted Date: 2024-12-19

Last Posted Date: 2024-12-27

Lead Sponsor: Minia University

Target Recruit Count: 150

Registration Number: NCT06741566

Dose-Dependent Effect of Intranasal Insulin in Humans Using Functional Magnetic Resonance Imaging (fMRI)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Intranasal insulin

First Posted Date: 2023-11-22

Last Posted Date: 2024-03-21

Lead Sponsor: Florian Schmitzberger

Target Recruit Count: 6

Registration Number: NCT06144255

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

COMMETS- Combination MCI Metabolic Syndrome

Phase 2

Recruiting

Conditions: Alzheimer Disease
Mild Cognitive Impairment
Metabolic Syndrome

Interventions: Drug: Semaglutide
Other: Semaglutide placebo
Other: Intranasal insulin placebo
Drug: Intranasal insulin

First Posted Date: 2023-10-10

Last Posted Date: 2024-03-22

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 80

Registration Number: NCT06072963

Locations: 🇮🇱
Joseph Sagol Neuroscience center, Sheba Medical Center, Ramat Gan, Israel

Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia

Not Applicable

Recruiting

Conditions: Schizophrenia
Healthy

Interventions: Drug: Intranasal insulin
Drug: Placebo

First Posted Date: 2023-03-01

Last Posted Date: 2024-08-20

Lead Sponsor: Centre for Addiction and Mental Health

Target Recruit Count: 20

Registration Number: NCT05748990

Locations: 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Intranasal Insulin Improves Postoperative Neurocognitive Disorders in Elderly Patients

Not Applicable

Recruiting

Conditions: Postoperative Neurocognitive Disorders

Interventions: Drug: Intranasal saline
Drug: Intranasal insulin

First Posted Date: 2022-11-14

Last Posted Date: 2022-11-14

Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Target Recruit Count: 438

Registration Number: NCT05613491

Locations: 🇨🇳
First Affiliated Hospital of Xian Jiaotong University, Xi'an, Shannxi, China

Dose-Finding Study of Intranasal Insulin in Healthy Participants Insulin in Healthy Participants

Phase 1

Completed

Conditions: Out-Of-Hospital Cardiac Arrest
Healthy

Interventions: Drug: Intranasal insulin

First Posted Date: 2021-09-30

Last Posted Date: 2022-10-14

Lead Sponsor: Robert Silbergleit

Target Recruit Count: 24

Registration Number: NCT05062785

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Effect of Intranasal Insulin on Postoperative Cognitive Dysfunction

Conditions: Middle Aged Patients

Interventions: Drug: Intranasal insulin

First Posted Date: 2019-11-06

Last Posted Date: 2019-11-06

Lead Sponsor: Minia University

Target Recruit Count: 57

Registration Number: NCT04154449

Locations: 🇪🇬
Minia university, Minya, Egypt
🇪🇬
Minia University, Minya, Egypt

Intranasal Insulin for Posttraumatic Stress Disorder

Phase 2

Recruiting

Conditions: PTSD

Interventions: Drug: Placebo
Drug: Intranasal insulin

First Posted Date: 2019-08-05

Last Posted Date: 2024-11-04

Lead Sponsor: VA Connecticut Healthcare System

Target Recruit Count: 20

Registration Number: NCT04044534

Locations: 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States

Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders

Phase 2

Completed

Conditions: Bipolar I Disorder
Psychosis
Schizo Affective Disorder
Schizophrenia

Interventions: Drug: Intranasal Insulin

First Posted Date: 2019-05-09

Last Posted Date: 2025-04-15

Lead Sponsor: Mclean Hospital

Target Recruit Count: 87

Registration Number: NCT03943537

Locations: 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States

"Effect of Central Insulin Administration on Whole-body Insulin Sensitivity in Women"

Not Applicable

Completed

Conditions: Insulin Sensitivity

Interventions: Drug: Placebo spray
Drug: intranasal insulin

First Posted Date: 2019-04-26

Last Posted Date: 2021-09-05

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 29

Registration Number: NCT03929419

Locations: 🇩🇪
University of Tuebingen, Department of Internal Medicine IV, Tuebingen, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy